Citadel Advisors
SKYE icon

Citadel Advisors’s Skye Bioscience SKYE Stock Holding History

Citadel Advisors’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.4K Buy
11,075
+6,187
+127% +$38.9K ﹤0.01% 13016
2026
Q1 		$24K Sell
4,888
-3,200
-40% -$20.9K ﹤0.01% 12631
2025
Q4 		$48.5K Buy
8,088
+4,563
+129% +$53.3K ﹤0.01% 12050
2025
Q3 		$111K Sell
3,525
-650
-16% -$19.6K ﹤0.01% 11776
2025
Q2 		$140K Buy
+4,175
New +$69.1K ﹤0.01% 11023
2025
Q1 		– Sell
-13
Closed -$283 – 15760
2024
Q4 		$283 Sell
13
-1,000
-99% -$33.4K ﹤0.01% 14355
2024
Q3 		$31.7K Buy
1,013
+875
+634% +$39.3K ﹤0.01% 12381
2024
Q2 		$8.81K Buy
+138
New +$13.1K ﹤0.01% 13165

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors's SKYE Position: Q4 2025 in Review

Citadel Advisors sold out of Skye Bioscience (SKYE) in Q4 2025, closing a stake of 3,607 shares — an estimated $42.1K sold.

Citadel Advisors first reported a position in SKYE in Q2 2024 and held it in 4 quarters. The position peaked at $2.13M in Q2 2024. 42 funds tracked by Wall St. Rank hold SKYE as of Q4 2025.

  • Citadel Advisors reported no remaining Skye Bioscience position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 3,607 Skye Bioscience shares in Q4 2025, an estimated $42.1K.
  • Citadel Advisors first reported a position in Skye Bioscience in Q2 2024 and held it in 4 quarters.
  • Citadel Advisors's Skye Bioscience position peaked at $2.13M in Q2 2024.
  • 42 funds tracked by Wall St. Rank held Skye Bioscience as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.